Theodoros Kelesidis1, Nicholas Jackson, Grace A McComsey, Xiaoyan Wang, David Elashoff, Michael P Dube, Todd T Brown, Otto O Yang, James H Stein, Judith S Currier. 1. aDavid Geffen School of Medicine at University of California - Los Angeles bUCLA Department of Medicine Statistics Core, Los Angeles, California cCase Western Reserve University, Cleveland, Ohio dKeck School of Medicine at the University of Southern California, Los Angeles, California eJohns Hopkins University, Baltimore, Maryland fUniversity of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Abstract
OBJECTIVE: The pathogenesis of immune dysfunction in chronic HIV-1 infection is unclear, and a potential role for oxidized lipids has been suggested. We hypothesize that both oxidized HDL and LDL (HDLox and LDLox) contribute to HIV-1-related immune dysfunction. STUDY: In the AIDS Clinical Trials Group A5260, 234 HIV-infected antiretroviral therapy (ART)-naive participants were randomized to receive tenofovir-emtricitabine and protease inhibitors or raltegravir and had HIV-1 RNA less than 50 copies/ml by week 24 and thereafter. METHODS: Associations between biomarkers of inflammation (IL-6, high-sensitivity C-reactive protein and D-dimer), immune activation (sCD163, sCD14, soluble IL-2 receptor, CD38 and HLA-DR), inflammatory monocytes (CD14CD16), T-cell senescence (CD28 and CD57) and exhaustion (PD1), and HDLox, LDLox were assessed at entry and after ART (week 96) with Spearman (partial) correlations. RESULTS:HDLox declined and LDLox increased over 96 weeks of ART. Positive associations were observed at baseline and over time between HDLox (but not consistently for LDLox) and most markers of inflammation and immune activation (but not senescence/exhaustion), even after adjustment for multiple comparisons, demographics, entry CD4 cell count and HIV-1 RNA. HDLox was positively associated with IL-6 (r = 0.19 - 0.29, P < 0.01) and sCD163 (r = 0.14 - 0.41, P ≤ 0.04) at all time points. CONCLUSION: These prospective longitudinal data suggest that oxidized lipoproteins may contribute to persistent immune activation on ART.
RCT Entities:
OBJECTIVE: The pathogenesis of immune dysfunction in chronic HIV-1 infection is unclear, and a potential role for oxidized lipids has been suggested. We hypothesize that both oxidized HDL and LDL (HDLox and LDLox) contribute to HIV-1-related immune dysfunction. STUDY: In the AIDS Clinical Trials Group A5260, 234 HIV-infected antiretroviral therapy (ART)-naive participants were randomized to receive tenofovir-emtricitabine and protease inhibitors or raltegravir and had HIV-1 RNA less than 50 copies/ml by week 24 and thereafter. METHODS: Associations between biomarkers of inflammation (IL-6, high-sensitivity C-reactive protein and D-dimer), immune activation (sCD163, sCD14, soluble IL-2 receptor, CD38 and HLA-DR), inflammatory monocytes (CD14CD16), T-cell senescence (CD28 and CD57) and exhaustion (PD1), and HDLox, LDLox were assessed at entry and after ART (week 96) with Spearman (partial) correlations. RESULTS: HDLox declined and LDLox increased over 96 weeks of ART. Positive associations were observed at baseline and over time between HDLox (but not consistently for LDLox) and most markers of inflammation and immune activation (but not senescence/exhaustion), even after adjustment for multiple comparisons, demographics, entry CD4 cell count and HIV-1 RNA. HDLox was positively associated with IL-6 (r = 0.19 - 0.29, P < 0.01) and sCD163 (r = 0.14 - 0.41, P ≤ 0.04) at all time points. CONCLUSION: These prospective longitudinal data suggest that oxidized lipoproteins may contribute to persistent immune activation on ART.
Authors: David A Zidar; Steven Juchnowski; Brian Ferrari; Brian Clagett; Heather A Pilch-Cooper; Shawn Rose; Benigno Rodriguez; Grace A McComsey; Scott F Sieg; Nehal N Mehta; Michael M Lederman; Nicholas T Funderburg Journal: J Acquir Immune Defic Syndr Date: 2015-06-01 Impact factor: 3.731
Authors: Michael M Lederman; Leonard Calabrese; Nicholas T Funderburg; Brian Clagett; Kathy Medvik; Hector Bonilla; Barbara Gripshover; Robert A Salata; Alan Taege; Michelle Lisgaris; Grace A McComsey; Elizabeth Kirchner; Jane Baum; Carey Shive; Robert Asaad; Robert C Kalayjian; Scott F Sieg; Benigno Rodriguez Journal: J Infect Dis Date: 2011-10-15 Impact factor: 5.226
Authors: Grace A McComsey; Carlee Moser; Judith Currier; Heather J Ribaudo; Pawel Paczuski; Michael P Dubé; Theodoros Kelesidis; Jennifer Rothenberg; James H Stein; Todd T Brown Journal: Clin Infect Dis Date: 2016-01-20 Impact factor: 9.079
Authors: Shubhendu Sen Roy; Huy Cong Xuan Nguyen; Thomas A Angelovich; Anna C Hearps; Diana Huynh; Anthony Jaworowski; Theodoros Kelesidis Journal: J Vis Exp Date: 2017-10-12 Impact factor: 1.355
Authors: Theodoros Kelesidis; Michael N Oda; Mark S Borja; Yumin Yee; Kit F Ng; Diana Huynh; David Elashoff; Judith S Currier Journal: J Acquir Immune Defic Syndr Date: 2017-07-01 Impact factor: 3.771
Authors: William Mu; Madhav Sharma; Rachel Heymans; Eleni Ritou; Valerie Rezek; Philip Hamid; Athanasios Kossyvakis; Shubhendu Sen Roy; Victor Grijalva; Arnab Chattopadhyay; Jeremy Papesh; David Meriwether; Scott G Kitchen; Alan M Fogelman; Srinivasa T Reddy; Theodoros Kelesidis Journal: AIDS Date: 2021-03-15 Impact factor: 4.632